3D Printed Drugs Market Size, Trends, Share, Growth | Report 2022-2030
The global 3D printed drugs market was valued at USD 72.25 million in 2021 and it is predicted to surpass around USD 269.97 million by 2030 with a CAGR of 15.77% from 2022 to 2030.
Report Highlights
The rising prevalence of chronic diseases, combined with the rising population of patients with dysphagia around the globe is pushing the demand for immediate soluble medications, which is likely to drive the market. For instance, according to a study published in April 2022, the prevalence of oropharyngeal dysphagia is high in conditions such as stroke and aging and is reported to be 26.19% in the elderly.
An increase in the aging population has led to the growing demand for the development of easy-to-swallow pills for the elderly. The 3D printed highly soluble and easy-to-swallow drugs can help the elderly who have difficulty swallowing. Moreover, according to the United Nations, the number of people aged 65 and more in 2050 is projected to be 1.5 billion. Thus, the growing elderly population across the world would propel the demand for easy-to-swallow drugs resulting in market growth.
Other factors such as quickly expanding demand for pharmaceuticals, technical improvements in healthcare, as well as the government's focus and expenditures in the 3D printing industry, are also contributing to the market's growth. For instance, in March 2022, Evonik Venture Capital invested in Nevada-based Laxxon Medical for the manufacturing of 3D-printed tablets. The latter company has developed a 3D screen-printing technology for the production of structured tablets with the controlled release of API over time. Such investments are likely to supplement the market growth in the coming years.
The COVID-19 pandemic is anticipated to positively impact market growth. Several printers have been launched by the operating companies in the advanced manufacturing industry to help increase the manufacturing of medications and other necessary products. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic.
The growing demand for personalized medicine is expected to majorly drive market growth in the coming years. As 3D printing of pharmaceutical drugs can produce personalized medicine in small batches with carefully tailored shapes, dosages, and sizes, the market is anticipated to grow at an exponential rate in the near future. In addition, the use of 3D printing technology can significantly reduce manufacturing costs thus, further increasing investments in this space.
On the other hand, adverse effects from these drugs, the use of 3D printing to create illegal drugs, and a lack of government restrictions for 3D printed products are limiting the market's growth. For instance, in March 2018, a police case was filed in Amsterdam, for the illegal handling of these drugs. However, increased awareness of the benefits of these medications, such as their immediate solubility, faster manufacturing time, reduced waste, and easy on-demand manufacturing is likely to create multiple prospects for market growth.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 72.25 million |
| Revenue Forecast by 2030 | USD 269.97 million |
| Growth rate from 2022 to 2030 | CAGR of 15.77% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Technology, application, end-use, region |
| Companies Covered | Aprecia; Formac Pharmaceuticals; Extend Biosciences; Affinity Therapeutics; Osmotica Pharmaceuticals; GSK Group of Companies; FabRx Ltd.; Hewlett Packard Caribe; Merck & Co., Inc.; Cycle Pharmaceuticals; AstraZeneca. |
Technology Insights
The zip dose segment held the highest share of the market in 2021. This drug technology is easy to use and beneficial to patients with dysphagia. Furthermore, an increasing requirement among geriatric & pediatric patients for rapid soluble drugs that disperse quickly in the mouth drives the market growth.
Inkjet printer technology, on the other hand, is anticipated to expand at the fastest rate during the projected period. As it generates 3D drugs at a steady rate and has technological superiorities over other techniques, it has a high adoption rate among patients. Inkjet printing is a method of depositing three-dimensional shapes in solid dosage forms by spraying various combinations of active pharmaceutical ingredients and excipients (inks) through a nozzle. Furthermore, increased epilepsy incidences continued technological advancements in 3D printing technology, and expanding awareness of this technology in emerging nations are primary market growth drivers.
Application Insights
The neurology segment dominated the market with a share of 49.9% in 2021. In August 2015, the U.S. FDA approved Aprecia Pharmaceutical’s SPRITAM (levetiracetam) tablets for the treatment of people with epilepsy. This is the only approved drug available on the market. This approval has gained the attention of pharmaceutical companies to invest in this segment thereby propelling the market growth.
The segment is also propelled by an increase in the prevalence of various neurological disorders such as Parkinson's disease. In an article published in April 2022, a team of scientists from Germany and the Netherlands used 3D printing technology for the manufacturing of Mini-Floating-Polypill as a therapy for Parkinson’s disease. Fused deposition modeling (FDM) was used for this study. Such research efforts are anticipated to supplement the segment growth.
On the other hand, orthopedic procedures are complex & tough, and new approaches are needed to overcome a slew of known issues and better patient outcomes. In addition, complications, particularly the high rate of infection, frequently result in extended patient suffering and functional loss. Thus, orthopedic drugs can be used to combat postoperative infections, hence, propelling the market growth.
End-use Insights
The hospitals & clinics segment captured the highest revenue share of the market in 2021. The widespread use of prescription pills to treat a variety of chronic diseases is moving the market for personalized pharmaceuticals forward. The segment is also being driven by the growing demand for pharmaceuticals and the cost-effective use of bio-drugs employing this technology.
Furthermore, in hospitals and clinics, these printers can be installed to enable the on-demand manufacturing of medications, specifically those with poor stability or that need to be stored in a cold chain. Additionally, it can considerably save expenses, waste, and environmental strain. These factors are anticipated to increase the adoption of 3D-printed drugs among hospitals and clinics.
Regional Insights
North America dominated the regional market with a share of 37.43% in 2021. This major share can be attributed to an increased incidence of chronic diseases, the presence of excellent domestic healthcare infrastructure, strong investment in R&D, and the expanding use of technological developments in the North America region.
The Asia Pacific is estimated to be the fastest-growing region due to significant developments by China and Japan in the technological integration of 3D printed drug methodologies. Moreover, the development of healthcare infrastructure, R&D, and clinical development frameworks of emerging economies such as India and Australia have poised the Asia Pacific market to witness lucrative opportunities and growth throughout the forecast period.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on 3D Printed Drugs Market
5.1. COVID-19 Landscape: 3D Printed Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global 3D Printed Drugs Market, By Technology
8.1. 3D Printed Drugs Market, by Technology, 2022-2030
8.1.1 Inkjet Printing
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Fused Deposition Modeling
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Stereolithography
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. ZipDose Technology
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global 3D Printed Drugs Market, By Application
9.1. 3D Printed Drugs Market, by Application, 2022-2030
9.1.1. Orthopedic
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Neurology
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Dental
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global 3D Printed Drugs Market, By End-use
10.1. 3D Printed Drugs Market, by End-use, 2022-2030
10.1.1. Hospitals & clinics
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research Laboratories
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global 3D Printed Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. Aprecia
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Extend Biosciences
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bioduro
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Affinity Therapeutics
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Osmotica Pharmaceuticals
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Aprecia Pharmaceuticals LLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. GlaxoSmithKline Plc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. FabRx Ltd
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hewlett Packard Caribe
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers